Gastric cancer (GC) is the fifth most common malignancy in the world, with an incidence of approximately 1 million new patients worldwide in 20221. Due to its aggressive behaviour and the late appearance of symptoms, such as bleeding, loss of appetite, weight loss, and abdominal pain, most patients have locally advanced and/or metastatic disease at first presentation. Especially in patients with diffuse-type GC, the peritoneum is the most common site of metastatic spread.
